Advertising Untitled Letter For Exeltis Slynd Social Media Spot Renews Attention To Online Risk Disclosure

 
• By Nielsen Hobbs

Oral contraceptive’s ad did not contain any risk information and was not submitted to US FDA beforehand, so the letter seems an easy call. But with two citations released in as many weeks, is the agency signaling an uptick in enforcement?

sylnd untitled letter feature image
OPDP gave Slynd's social media advertising the thumbs down. • Source: Nielsen Hobbs; the Pink Sheet | images from Shutterstock, FDA

More from Marketing & Advertising

More from Compliance